Myelodysplastic Syndromes (MDS)

Furha Cossor, MD

Institution
Saint Lukes's
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Furha Cossor, MD, is a board-certified oncologist and hematologist with Saint Luke's Cancer Specialists. Dr. Cossor has a special interest in multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, and myeproliferative neoplasms.

Anand B. Karnad, MD

Institution
UT Health San Antonio MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

My career since completing my fellowship training in Hematology and Medical Oncology at Boston City Hospital has been devoted to being a clinician-educator passionate about clinical trials as the best option for care. I have led Divisions of Hematology-Oncology at ETSU and at UT Health San Antonio and have played leadership roles in the Cancer Centers at both institutions. My current career focus is on hematology (blood disorders) spanning classical (or benign) hematology and all related pre-malignant and malignant disorders of the blood, bone marrow, lymph nodes, and immune system.

Ludovica Marando, MD

Institution
Harris Health System at Baylor College of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Dr. Marando is a Hematologist in Houston, Texas. Dr. Marando is a dedicated hematologist who is passionate about understanding the mechanisms that govern somatic clonal mosaicism within the hematopoietic stem cell compartment and the factors that govern progression into overt myeloid neoplasms. I do firmly believe that a better understanding of these mechanisms can lead to a shift in treatment paradigms: prevention of deadly hematological cancers.

Satyajit Kosuri, MD

Institution
Duchossois Center for Advanced Medicine - Hyde Park
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
About

Satyajit Kosuri, MD, is a medical oncologist who treats adult patients with acute leukemia, myelodysplastic syndrome and myelofibrosis. He is an expert in stem cell transplantation (also known as bone marrow transplant) and leads the Graft-Versus-Host Disease (GVHD) Clinic, a program designed to prevent and treat GVHD, a complication of allogeneic stem cell transplant. His clinical research focuses on improving patient access to transplant through the use of alternative donor strategies and the use of novel immune therapies in these diseases. His main passion is guiding his patients through

Brion V. Randolph, MD

Institution
University of Tennessee Health Science Center at Baptist Memorial Hospital in Memphis
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Dr. Brion Randolph is a medical oncologist and hematologist with 23 years of experience treating patients with cancer and blood disorders. His expertise encompasses both oncology and hematology, allowing him to provide comprehensive care for patients facing complex diagnoses. Dr. Randolph focuses on delivering personalized treatment plans for individuals dealing with various forms of cancer and blood-related conditions.

Venetoclax-Based RIC Transplant and Maintenance Is Feasible in Poor-Risk MDS and AML

Original Publication Date
Article Source
External Web Content

Posttransplant maintenance with venetoclax (Venclexta) plus decitabine (Dacogen) and cedazuridine (Inqovi) following a reduced-intensity conditioning (RIC) transplant regimen of venetoclax plus fludarabine and busulfan (FluBu2), along with tacrolimus (Prograf) plus methotrexate…

Meta-Analysis Underscores Role of Luspatercept for Anemia in Lower-Risk MDS

Original Publication Date
Article Source
External Web Content

Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS. Data from a systematic review and meta-analysis of 20 studies demonstrated that luspatercept-aamt (Reblozyl) yielded high red blood…

Akriti Jain, M.D

Institution
Cleveland Clinic
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Akriti G Jain, MD treats myeloid disorders at Cleveland Clinic’s Main Campus in Cleveland, Ohio. She has a personal interest in taking care of patients with Myeloproliferative Neoplasms including Chronic Myeloid Leukemia. Her passion lies in understanding the needs of every patient and always prioritizing and advocating for her patients and their families. Her patient care philosophy involves offering in-depth explanation regarding diagnoses and to engage in active partnership with her patients and their referring providers to personalize decision-making and monitoring given the nature of the

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.